Cardiovascular Institute

Stanford Transcatheter Heart Valve Program

A new therapeutic catheter-based technology for the treatment of valvular heart disease

Stanford Transcatheter Heart Valve Program

Stanford has been performing transcatheter aortic valve replacement (TAVR) since 2008 and has treated nearly 200 patients as part of the PARTNER Trial using the Edwards balloon expandable SAPIEN valve. Beginning in 2012, Stanford has also been performing TAVR on a commercial basis in patients with symptomatic critical aortic stenosis who are not candidates for open surgical aortic valve replacement (AVR).

Stanford not only offers transfemoral TAVR in these patients, but also the transapical (TA) and direct transaortic (TAO) approaches for patients with inadequate iliac access. Stanford also now performs "valve in valve" TAVR for patients with failing surgically placed bioprosthetic valves. This is a major clinical need because these patients with failing tissue valves constitute a high risk patient group.

An FDA panel recommended approval of SAPIEN TAVR in high risk, but operable (STS > 8%, PARTNER Cohort A) patients with critical aortic stenosis on June 13, 2012. The FDA officially approved the SAPIEN valve for commercial TAVR use in this larger subset of patients on November 1, 2011. As the only PARTNER Trial TAVR site in the Northern California region, Stanford also has the unique ability to perform TAVR in moderate-risk aortic stenosis patients as part of the PARTNER 2A Trial randomizing patients with an STS predicted 30-day mortality of only 4% or greater to TAVR using the new 18Fr and 19Fr transfemoral NovaFlex delivery systems and the SAPIEN XT transcatheter valve or to open surgical AVR.

For more information, please refer to the Stanford Transcatheter Heart Valve Program fact sheet and letter for referring physicians.

Stanford Medicine Resources:

Footer Links: